Newsroom | 20556 results
Sorted by: Latest
-
Ataraxis AI to Present Nine Studies at SABCS 2026
NEW YORK--(BUSINESS WIRE)--Ataraxis AI, a company building clinical AI tools to personalize cancer care, announced today that it will present nine studies at the 2026 San Antonio Breast Cancer Symposium (SABCS), including several oral presentations. The research validates Ataraxis AI for prognosis and chemotherapy benefit prediction in the landmark Phase III TAILORx and SWOG-8814 trials and in multi-national real-world cohorts, with head-to-head comparisons against legacy genomic assays. Ataraxi...
-
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on November 16, 2026, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award...
-
PANCAID Consortium Adopts biomodal's duet 6-base mosaic Technology to Advance Early Detection of Pancreatic Cancer
CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--biomodal, an omics-based life sciences technology and analytics company, today announced that PANCAID (PANcreatic CAncer Initial Detection via liquid biopsy), a pan-European research consortium uniting 18 partner institutions across eight countries, has adopted biomodal’s duet 6-base mosaic sequencing technology to explore complementary genetic, epigenetic and fragmentomic biomarkers in circulating cell-free DNA (cfDNA) from patients with pancrea...
-
Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium
CHICAGO--(BUSINESS WIRE)--Tempus today announced that 16 abstracts leveraging its diagnostic capabilities and extensive multimodal database will be presented at SABCS....
-
Nanoscope Therapeutics Partners with Uniphar to Expand Access to MOGENRY® Across the Gulf Cooperation Council Region
DALLAS & DUBLIN--(BUSINESS WIRE)--Nanoscope Therapeutics, Inc. (“Nanoscope”), a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that it has entered into an agreement with Uniphar, a global healthcare services partner to the pharmaceutical, biotech and medtech industries, under which Uniphar will serve as Nanoscope’s exclusive named patient s...
-
Signature Biologics alerta o público sobre o uso não autorizado do nome e da imagem do seu presidente, Dr. Neil Riordan
IRVING, Texas--(BUSINESS WIRE)--A Signature Biologics, LLC, desenvolvedora e fabricante de produtos celulares e biológicos sediada em Irving, alerta pacientes e o público em geral que empresas não afiliadas estão utilizando o nome, a fotografia e conteúdos em vídeo do seu fundador e presidente, Dr. Neil Riordan — sem o conhecimento ou consentimento dele ou da empresa, e de maneira falsa e enganosa — para promover seus próprios produtos e serviços à base de células-tronco. Essas empresas têm uti...
-
Signature Biologics advierte al público sobre el uso no autorizado del nombre y la imagen de su presidente, el Dr. Neil Riordan
IRVING, Texas--(BUSINESS WIRE)--Signature Biologics, LLC, empresa con sede en Irving dedicada al desarrollo y la fabricación de productos celulares y biológicos, advierte a los pacientes y al público en general que empresas sin vinculación con ella están utilizando el nombre, las fotografías y el contenido audiovisual de su fundador y presidente, el Dr. Neil Riordan, sin su conocimiento ni consentimiento, y de manera falsa y engañosa, para promocionar sus propios productos y servicios con célul...
-
Dyno Therapeutics Unveils In Vivo Genetic Payload Screening Service and Lambda-1 Capsid World Model, Expanding AI-Powered Gene Delivery Tools at GATC 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics unveils in vivo genetic payload screening service and Lambda-1 capsid world model, expanding AI-powered gene delivery tools at GATC...
-
Dyno Therapeutics Expands Frontiers Network with Multiple Global Options to Accelerate Path to Clinical Proof of Concept at GATC 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics expands Frontiers Network with multiple global options to accelerate path to clinical proof of concept at GATC 2026...
-
Riassunto: TreeFrog Therapeutics nomina James Sterling Direttore finanziario
BORDEAUX, Francia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--TreeFrog Therapeutics, società biotecnologica che sviluppa terapie cellulari scalabili basate sulla sua tecnologia proprietaria C-Stem™, oggi ha annunciato la nomina di James Sterling all'incarico di Direttore finanziario, a partire dal 1° novembre 2026. James entra a far parte del team dirigente di TreeFrog e riferisce a Mark Rothera, Presidente e Amministratore delegato. Sterling dirige gli aspetti finanziari, le relazioni con gli investi...